Oruka Therapeutics (NASDAQ:ORKA) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Oruka Therapeutics (NASDAQ:ORKA) from a hold rating to a sell rating in a research report sent to investors on Sunday.

ORKA has been the subject of several other research reports. Piper Sandler began coverage on shares of Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 target price for the company. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a report on Thursday, November 13th. They set a “buy” rating and a $45.00 price target on the stock. UBS Group initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective for the company. BTIG Research increased their price objective on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Wedbush lifted their target price on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $54.50.

Oruka Therapeutics Trading Down 0.6%

NASDAQ ORKA opened at $32.97 on Friday. The firm has a market capitalization of $1.60 billion, a P/E ratio of -17.35 and a beta of -0.38. The business has a fifty day simple moving average of $32.42 and a 200 day simple moving average of $26.98. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $36.53.

Insider Transactions at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00. Following the sale, the insider owned 34,018 shares of the company’s stock, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 21,000 shares of company stock worth $663,530. Corporate insiders own 24.69% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ORKA. Viking Global Investors LP bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $51,280,000. Paradigm Biocapital Advisors LP bought a new stake in Oruka Therapeutics during the 4th quarter worth approximately $51,840,000. Remedium Capital Partners LLC bought a new stake in Oruka Therapeutics during the 4th quarter worth approximately $47,054,000. Avoro Capital Advisors LLC purchased a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $25,640,000. Finally, Deep Track Capital LP boosted its holdings in Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after purchasing an additional 735,983 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.